Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : How high will Microsoft fly? -- Ignore unavailable to you. Want to Upgrade?

To: t2 who wrote (23923)	6/9/1999 11:13:00 PM
From: Sir Francis Drake	Respond to of 74651

<OT> t2K - the fall-back in PFE is unfortunate only because you could have gotten it at a lower price. The Trovan issue has already been hinted at before (based on European data), and was factored in, but the FDA announcement is what caused the problem. Remember, PFE is almost 30% off it's high - so the downside is not huge. As I wrote before, personally, I feel that PFE under 105 is a buy - and, that while there is a chance that it may break 100 at some point, I am not sure about the timing. This may actually be the worst of it, unless there is some kind of market meltdown. I picked up CSCO and have traded it a couple of times, because I want to actually own the stock - but as usual, I would like to lower my average cost (I feel that $64 average would be good for a long term holding). Morgan